## IN THE CLAIMS

Please amend the claims as follows:

Claims 1-3 (Cancelled)

Claim 4 (Previously Presented): A peptide consisting of a sequence selected from the sequences of SEQ ID No. 1 to SEQ ID No. 10.

Claim 5 (Cancelled)

Claim 6 (Currently Amended): The peptide according to Claim 4 [[62]], wherein a tripeptide sequence is <u>further</u> linked to the N-terminal end of the <u>peptide</u> sequence (I), wherein <u>and</u> said tripeptide sequence is selected from the group consisting of Gly-Ser-Cys-, Gly-Ser-Thr-, Gly-Ser-Pro-, Gly-Ser-Ser-, Gly-Ser-Gly-, and Gly-Ser-Gln-.

Claim 7 (Currently Amended): The peptide according to Claim 4 [[62]], wherein a tetrapeptide sequence is <u>further</u> linked to the N-terminal end of the <u>peptide</u> sequence (I), wherein <u>and</u> said tetrapeptide sequence is selected from the group consisting of Gly-Ser-Gly-Cys- (SEQ ID NO: 17), Gly-Cys-Gly-Ser- (SEQ ID NO: 18), Gly-Ser-Gly-Ser- (SEQ ID NO: 19), and Gly-Cys-Gly-Cys- (SEQ ID NO: 20).

Claim 8 (Currently Amended): A peptide consisting of the sequence of SEQ ID No. 11 [[or]], SEQ ID No. 12, SEQ ID No. 13, or SEQ ID No. 14.

Claims 9-14 (Cancelled)

Claim 15 (Currently Amended): A chemical assembly with affinity for a phospholipid, comprising at least two peptides as defined in Claim 4 [[62]], which may be identical or different, said peptides being are linked to one another.

Claims 16-18 (Cancelled)

Claim 19 (Currently Amended): A labeling compound comprising a peptide as defined in Claim 4 [[62]], coupled to a labeling molecule or to nanoparticles that are dense in electron microscopy.

Claim 20 (Previously Presented): A labeling compound comprising a chemical assembly as defined in Claim 15, coupled to a labeling molecule or to nanoparticles that are dense in electron microscopy, wherein the labeling molecule or the nanoparticles label the chemical assembly.

Claim 21 (Previously Presented): The labeling compound according to Claim 19, in which the labeling molecule is a fluorescent molecule.

Claim 22 (Previously Presented): The labeling compound according to Claim 19, in which the labeling molecule consists of one of the partners of the avidin-biotin system.

Claim 23 (Previously Presented): The labeling compound according to Claim 19, in which the labeling molecule is a radio element.

Claim 24 (Previously Presented): The labeling compound according to Claim 19, in which the labeling molecule is a contrast agent in magnetic resonance imaging.

Claim 25 (Previously Presented): The labeling compound according to Claim 19, in which the labeling molecule is technetium.

Claim 26 (Previously Presented): The labeling compound according to Claim 19, in which the nanoparticles that are dense in electron microscopy are gold nanoparticles.

Claim 27 (Previously Presented): A diagnostic kit comprising a compound according to Claim 19.

Claim 28 (Previously Presented): A diagnostic kit according to Claim 27, also comprising a suitable reagent for detecting said labeling molecule.

Claim 29 (Currently Amended): A kit for analyzing and detecting negative charges at the surface of cells, comprising a peptide according to Claim 4 [[62]].

Claim 30 (Previously Presented): A kit for analyzing and detecting negative charges at the surface of cells, comprising a chemical assembly according to Claim 15.

Claim 31 (Currently Amended): A kit for analyzing and detecting microvesicules in the blood, comprising a peptide according to Claim 4 [[62]].

Claim 32 (Previously Presented): A kit for analyzing and detecting microvesicules in the blood, comprising a chemical assembly according to Claim 15.

Claim 33 (Previously Presented): The kit according to Claim 29, in which the peptide is coupled to a label.

Claim 34 (Previously Presented): The kit according to Claim 30, in which the assembly is coupled to a label.

Claim 35 (Currently Amended): A filter for dialyzing activated circulating blood cells, said filter comprises the peptide according to Claim 4 [[62]].

Claim 36 (Previously Presented): A peptide comprising the peptide according to Claim 4 and a tripeptide sequence which is linked to the N-terminal end of the peptide according to Claim 4, wherein said tripeptide sequence is selected from the group consisting of Gly-Ser-Cys-, Gly-Ser-Thr-, Gly-Ser-Pro-, Gly-Ser-Ser-, Gly-Ser-Gly-, and Gly-Ser-Gln-.

Claim 37 (Previously Presented): A peptide comprising the peptide according to Claim 4 and a tetrapeptide sequence which is linked to the N-terminal end of the peptide according to Claim 4, wherein said tetrapeptide sequence is selected from the group consisting of Gly-Ser-Gly-Cys-, Gly-Cys-Gly-Ser-, Gly-Ser-Gly-Ser-, Gly-Cys-Gly-Cys- or Gly-Cys-Gly-Ser-.

Claims 38-51 (Cancelled)

Claims 52 (Previously Presented): The labeling compound according to Claim 20, in which the labeling molecule is a fluorescent molecule.

Claim 53 (Previously Presented): The labeling compound according to Claim 20, in which the labeling molecule consists of one of the partners of the avidin-biotin system.

Claim 54 (Previously Presented): The labeling compound according to Claim 20, in which the labeling molecule is a radio element.

Claim 55 (Previously Presented): The labeling compound according to Claim 20, in which the labeling molecule is a contrast agent in magnetic resonance imaging.

Claim 56 (Previously Presented): The labeling compound according to Claim 20, in which the labeling molecule is technetium.

Claim 57 (Previously Presented): The labeling compound according to Claim 20, in which the nanoparticles that are dense in electron microscopy are gold nanoparticles.

Claim 58 (Previously Presented): A diagnostic kit comprising the labeling compound according to Claim 20.

Claim 59 (Previously Presented): The diagnostic kit according to Claim 58, also comprising a suitable reagent for detecting said labeling molecule.

Claim 60 (Previously Presented): The kit according to Claim 31, in which the peptide is coupled to a label.

Claim 61 (Previously Presented): The kit according to Claim 32, in which the assembly is coupled to a label.

Claim 62 (Cancelled):

Claim 63 (New): A chemical assembly with affinity for a phospholipid, comprising at least two peptides as defined in Claim 36, which may be identical or different, said peptides being linked to one another.

Claim 64 (New): A chemical assembly with affinity for a phospholipid, comprising at least two peptides as defined in Claim 37, which may be identical or different, said peptides being linked to one another.

Claim 65 (New): A chemical assembly with affinity for a phospholipid, comprising at least two peptides as defined in Claim 8, which may be identical or different, said peptides being linked to one another.

Claim 66 (New): A labeling compound comprising a peptide as defined in Claim 36, coupled to a labeling molecule or to nanoparticles that are dense in electron microscopy.

Claim 67 (New): A labeling compound comprising a peptide as defined in Claim 37, coupled to a labeling molecule or to nanoparticles that are dense in electron microscopy.

Claim 68 (New): A labeling compound comprising a peptide as defined in Claim 8, coupled to a labeling molecule or to nanoparticles that are dense in electron microscopy.

Claim 69 (New): The labeling compound according to Claim 66, wherein the labeling molecule is selected from the group consisting of a fluorescent molecule, one of the partners of the avidin-biotin system, a radio element, a contrast agent in magnetic resonance imaging, and technetium, or wherein the nanoparticles that are dense in electron microscopy are gold nanoparticles.

Claim 70 (New): The labeling compound according to Claim 67, wherein the labeling molecule is selected from the group consisting of a fluorescent molecule, one of the partners of the avidin-biotin system, a radio element, a contrast agent in magnetic resonance imaging, and technetium, or wherein the nanoparticles that are dense in electron microscopy are gold nanoparticles.

Claim 71 (New): The labeling compound according to Claim 68, wherein the labeling molecule is selected from the group consisting of a fluorescent molecule, one of the partners of the avidin-biotin system, a radio element, a contrast agent in magnetic resonance imaging, and technetium, or wherein the nanoparticles that are dense in electron microscopy are gold nanoparticles.

Claim 72 (New): A labeling compound comprising a chemical assembly as defined in Claim 63, coupled to a labeling molecule or to nanoparticles that are dense in electron microscopy, wherein the labeling molecule or the nanoparticles label the chemical assembly.

Claim 73 (New): A labeling compound comprising a chemical assembly as defined in Claim 64, coupled to a labeling molecule or to nanoparticles that are dense in electron microscopy, wherein the labeling molecule or the nanoparticles label the chemical assembly.

Claim 74 (New): A labeling compound comprising a chemical assembly as defined in Claim 65, coupled to a labeling molecule or to nanoparticles that are dense in electron microscopy, wherein the labeling molecule or the nanoparticles label the chemical assembly.

Claim 75 (New): The labeling compound according to Claim 72, wherein the labeling molecule is selected from the group consisting of a fluorescent molecule, one of the partners of the avidin-biotin system, a radio element, a contrast agent in magnetic resonance imaging, and technetium, or wherein the nanoparticles that are dense in electron microscopy are gold nanoparticles.

Claim 76 (New): The labeling compound according to Claim 73, wherein the labeling molecule is selected from the group consisting of a fluorescent molecule, one of the partners of the avidin-biotin system, a radio element, a contrast agent in magnetic resonance imaging, and technetium, or wherein the nanoparticles that are dense in electron microscopy are gold nanoparticles.

Claim 77 (New): The labeling compound according to Claim 74, wherein the labeling molecule is selected from the group consisting of a fluorescent molecule, one of the partners of the avidin-biotin system, a radio element, a contrast agent in magnetic resonance imaging, and technetium, or wherein the nanoparticles that are dense in electron microscopy are gold nanoparticles.

Claim 78 (New): A diagnostic kit comprising a compound according to Claim 66.

Claim 79 (New): A diagnostic kit comprising a compound according to Claim 67.

Claim 80 (New): A diagnostic kit comprising a compound according to Claim 68.

Claim 81 (New): A kit for analyzing and detecting negative charge at the surface of cells, comprising a peptide according to Claim 36.

Claim 82 (New): A kit for analyzing and detecting negative charge at the surface of cells, comprising a peptide according to Claim 37.

Claim 83 (New): A kit for analyzing and detecting negative charge at the surface of cells, comprising a peptide according to Claim 8.

Claim 84 (New): A kit for analyzing and detecting negative charge at the surface of cells, comprising a chemical assembly according to Claim 63.

Claim 85 (New): A kit for analyzing and detecting negative charge at the surface of cells, comprising a chemical assembly according to Claim 64.

Claim 86 (New): A kit for analyzing and detecting negative charge at the surface of cells, comprising a chemical assembly according to Claim 65.

Application No. 10/518,383

Reply to Office Action of April 8, 2010

Claim 87 (New): A filter for dialyzing activated circulating blood cells, said filter comprises the peptide according to Claim 36.

Claim 88 (New): A filter for dialyzing activated circulating blood cells, said filter comprises the peptide according to Claim 37.

Claim 89 (New): A filter for dialyzing activated circulating blood cells, said filter comprises the peptide according to Claim 8.

11